- Trials with a EudraCT protocol (44,376)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
44,376 result(s) found.
Displaying page 1,933 of 2,219.
| EudraCT Number: 2020-002271-36 | Sponsor Protocol Number: MEPIC | Start Date*: 2021-03-09 |
| Sponsor Name:Danderyd Hospital | ||
| Full Title: Mepivacaine for pain relief at insertion of intrauterine contraception (MEPIC) – a triple-blind randomized controlled trial. | ||
| Medical condition: Insertion of intrauterine contraception | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-004911-79 | Sponsor Protocol Number: AR-01 | Start Date*: 2007-10-17 | |||||||||||
| Sponsor Name:cliniques Universitaires st luc-ucl | |||||||||||||
| Full Title: Pharmacodynamics of Fondaparinux subcutaneous versus continuous intravenous infusion in critically ill patients with or without vasopressors. | |||||||||||||
| Medical condition: Thromboprophylaxis to critically ill patients hospitalized in ICU with or without vasopressors | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-022065-10 | Sponsor Protocol Number: SABO-2010-01 | Start Date*: 2011-08-02 | |||||||||||
| Sponsor Name:Sahlgrenska University Hospital | |||||||||||||
| Full Title: Effect of angiogenesis inhibiting therapy in patients progressing on endocrine treatment and patients with triple negative breast cancer - a translational phase II study within the Swedish Associa... | |||||||||||||
| Medical condition: Patients with breast cancer who are oestrogen receptor positive but HER2 negative and progressing on endocrine therapy. Patients with locally advanced or recurrent triple negative breast cancer (TN... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: SE (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-004545-91 | Sponsor Protocol Number: 59874 | Start Date*: 2017-04-13 |
| Sponsor Name:VU University Medical Center, department of reproductive Medicine | ||
| Full Title: Continuous use of Oral contraceptives as an alternative for long term Pituitary down-regulation with GnRH agonist prior to IVF/ICSI in Endometriosis patients: a randomised controlled trial (COPIE t... | ||
| Medical condition: The research population consists of women with surgically confirmed endometriosis ASRM stage III or IV or endometrioma on transvaginal ultrasound or MRI, scheduled for an IVF/ICSI treatment. | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-002884-24 | Sponsor Protocol Number: Quadruple-P-Study | Start Date*: 2017-09-06 | |||||||||||||||||||||||||||||||
| Sponsor Name:AMC | |||||||||||||||||||||||||||||||||
| Full Title: Pessary or Progesterone to Prevent Preterm delivery in women with short cervical length | |||||||||||||||||||||||||||||||||
| Medical condition: preterm birth | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||||||||||||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2017-003560-13 | Sponsor Protocol Number: OTL-2016-OTL38-005 | Start Date*: 2017-10-18 | |||||||||||
| Sponsor Name:On Target Laboratories, LLC | |||||||||||||
| Full Title: A Phase 2, Single dose, Open-Label, Exploratory Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules | |||||||||||||
| Medical condition: adenocarcinoma lung cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-003581-26 | Sponsor Protocol Number: DuoCOMT2008-05-27 | Start Date*: 2008-07-18 | |||||||||||
| Sponsor Name:Dept of Neuroscience, Uppsala University | |||||||||||||
| Full Title: Pharmacokinetics of levodopa using duodenal levodopa/carbidopa infusion with and without oral COMT inhibitors | |||||||||||||
| Medical condition: Parkinson's disease (G20.9), advanced, patients presently on Duodopa treatment. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-005819-18 | Sponsor Protocol Number: DysBot | Start Date*: 2009-06-30 | |||||||||||
| Sponsor Name:Department of Neuroscience, Uppsala University | |||||||||||||
| Full Title: A comparison of Dysport (100 U/ml) and Botox (100 U/ml) using dose conversion factor 3:1 and 1.7:1 in the treatment of cervical dystonia. | |||||||||||||
| Medical condition: Cervical dystonia, not multifocal or generalised dystonia. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-004682-39 | Sponsor Protocol Number: KFJ-2020-02_NORMOSANG | Start Date*: 2020-11-16 |
| Sponsor Name:Thomayerova nemocnice | ||
| Full Title: Pilot, open-label, monocentric study evaluating safety and clinical effect of application of NORMOSANG® in patients with COVID-19 disease | ||
| Medical condition: Patients with COVID -19 disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: CZ (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-001832-27 | Sponsor Protocol Number: AT-202 | Start Date*: 2023-01-20 | ||||||||||||||||
| Sponsor Name:Allecra Therapeutics SAS | ||||||||||||||||||
| Full Title: A Single Group Treatment, Phase 2 study to investigate Pharmacokinetics, Safety and Tolerability of Cefepime-Enmetazobactam administered by intra-venous infusion over 2 hours in Male or Female Part... | ||||||||||||||||||
| Medical condition: Complicated urinary tract infections including acute pyelonephritis | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
| Trial protocol: CZ (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) SK (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2018-002851-14 | Sponsor Protocol Number: QUIWI | Start Date*: 2019-06-21 | |||||||||||
| Sponsor Name:FUNDACIÓN PETHEMA | |||||||||||||
| Full Title: A 2:1 randomized phase II trial to compare the efficacy and safety of standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in adult patients with newly diagnosed FLT3 wi... | |||||||||||||
| Medical condition: Acute myeloid leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) PT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-003381-14 | Sponsor Protocol Number: AIHBUDPRED1.0 | Start Date*: 2020-02-19 |
| Sponsor Name:Umeå University Hospital | ||
| Full Title: Budesonide versus Prednisolone as Primary Treatment for Autoimmune Hepatitis: An Open-label, Randomized, Prospective Multicenter 12-month Clinical Trial Evaluating Effect and Side-Effects. | ||
| Medical condition: Autoimmune hepatitis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-003425-30 | Sponsor Protocol Number: EPX-100-001 | Start Date*: 2022-07-27 |
| Sponsor Name:Epygenix Therapeutics, Inc. | ||
| Full Title: A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole HCl) as Adjunctive Therapy in Patients with Dravet Syndrome (ARGUS trial) | ||
| Medical condition: Dravet Syndrome | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Temporarily Halted) HU (Trial now transitioned) PL (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-000286-23 | Sponsor Protocol Number: MS200662_0001 | Start Date*: 2016-04-27 | |||||||||||||||||||||
| Sponsor Name:Telios Pharma, Inc. | |||||||||||||||||||||||
| Full Title: Phase I/II, First in Human, Dose Escalation Trial of TL-895 in Subjects with Relapsed/Refractory B-Cell Malignancies and Expansion in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia ... | |||||||||||||||||||||||
| Medical condition: B Cell Malignancies and Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) HU (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2021-003810-38 | Sponsor Protocol Number: KCP-8602-801 | Start Date*: 2021-12-01 | |||||||||||||||||||||||||||||||
| Sponsor Name:Karyopharm Therapeutics Inc. | |||||||||||||||||||||||||||||||||
| Full Title: Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients with Newly Diagnosed and Relapsed/R... | |||||||||||||||||||||||||||||||||
| Medical condition: High-risk primary refractory MDS patients | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: FR (Completed) IT (Prematurely Ended) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2015-001200-55 | Sponsor Protocol Number: 564038 | Start Date*: 2015-09-23 |
| Sponsor Name:Region Östergötland | ||
| Full Title: A single postoperative bisphosphonate infusion to improve patient reported function after hip or knee replacement. | ||
| Medical condition: Prosthetic loosening of hip and knee arthroplasty | ||
| Disease: | ||
| Population Age: Elderly | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-005525-23 | Sponsor Protocol Number: 54767414MMY3003 | Start Date*: 2014-04-24 | |||||||||||
| Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
| Full Title: Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma | |||||||||||||
| Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) BE (Completed) NL (Completed) DK (Completed) PL (Completed) GR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-001779-15 | Sponsor Protocol Number: BGB-A317-Sitravatinib-301 | Start Date*: 2022-11-15 |
| Sponsor Name:BeiGene, Ltd. | ||
| Full Title: A Randomized Phase 3 Study of Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Progressed on or After Platinum-Based Che... | ||
| Medical condition: Locally Advanced or Metastatic Non-Small Cell Lung Cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Prematurely Ended) FR (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2007-005109-23 | Sponsor Protocol Number: AWC LowE | Start Date*: 2009-08-05 | |||||||||||||||||||||
| Sponsor Name:Uppsala University Hospital | |||||||||||||||||||||||
| Full Title: Low-Dose Hormone Therapy Initiated early after Menopause and Changes in Artery Wall Composition (AWC), as Assesssed by High-Frequency Ultrasound. | |||||||||||||||||||||||
| Medical condition: Age/menopause related changes in the artery wall composition after menopause | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||||||||||||
| Trial protocol: SE (Prematurely Ended) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2005-005645-19 | Sponsor Protocol Number: 20051130 | Start Date*: 2007-09-12 |
| Sponsor Name:Dept of ped hem/onc | ||
| Full Title: RCT of oral ibuprofen for procedural anxiety, distress and pain in children with cancer | ||
| Medical condition: Pain and anxiety relief before needle insertion in a subcutanously implanted iv port in children with cancer. | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.